Why are our medicines so expensive? Spoiler: Not for the reasons you are being told…

References

• Roy V, King L. Betting on hepatitis C: how financial speculation in drug development influences access to medicines. BMJ. 2016;354:1. doi:10.1136/bmj.i3718.
   Google Scholar
• 10 Most Expensive Drugs in the US, Period. GoodRx. [cited 2023 Aug 7]. Available from: https://www.goodrx.com/healthcare-access/drug-cost-and-savings/most-expensive-drugs-period.
   Google Scholar
• Schwartländer B, Grubb I, Perriëns J. The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world. Lancet. 2006;368(9534):541–9. doi:10.1016/S0140-6736(06)69164-2.
   PubMed Web of Science ®Google Scholar
• MSF Access Campaign. A worldwide revolt for access. Access Campaign: 20 years. 2019. [cited 2023 Dec 5]. Available from: https://msfaccess.org/worldwide-revolt-access.
   Google Scholar
• Perez-Casas C, Macé C, Berman D, et al. Untangling the web of antiretroviral price Reductions 1st edition. 2001. [cited 2023 Dec 5]. Available from: https://msfaccess.org/untangling-web-antiretroviral-price-reductions-1st-edition.
   Google Scholar
• Hitting HIV hard with HAART therapy. | NIH Intramural Research Program. [cited 2023 Aug 1]. Available from: https://irp.nih.gov/accomplishments/hitting-hiv-hard-with-haart-therapy.
   Google Scholar
• Roser M, Ritchie H. HIV/AIDS. Our World in Data 2018; published online April 3. [cited 2023 Aug 7]. Available from: https://ourworldindata.org/hiv-aids.
   Google Scholar
• Documentary: Fire in the Blood. Sparkwater India, 2013. [cited 2023 Aug 7]. Available from: https://www.imdb.com/title/tt1787067/.
   Google Scholar
• UNAIDS. Global HIV & AIDS statistics—Fact sheet. [cited 2023 Dec 5]. Available from: https://www.unaids.org/en/resources/fact-sheet.
   Google Scholar
• Torreele E, Kazatchkine M, Liu J, et al. Stopping epidemics when and where they occur. Lancet. 2023;401(10374):324–328. doi:10.1016/S0140-6736(23)00015-6.
   PubMed Web of Science ®Google Scholar
• Cohen J. ‘I’m still feeling that we’re failing’: exasperated WHO leader speaks out about vaccine inequity. Science. 2021;372(6549):1376–1377. doi:10.1126/science.372.6549.1376.
   Web of Science ®Google Scholar
• ’t Hoen E. Private patents and public-health. 2016 [cited 2023 Aug 7]. Available from: https://haiweb.org/wp-content/uploads/2016/07/Private-Patents-Public-Health.pdf.
   Google Scholar
• Guellec D, van Pottelsberghe de la Potterie B. The economics of the European patent system: IP policy for innovation and competition. Oxford, UK: Oxford University Press, 2007 doi:10.1093/acprof:oso/9780199216987.001.0001.
   Google Scholar
• Drahos P. Global property rights in information: the story of trips at the gatt. Prometheus. 1995;13(1):6–19. doi:10.1080/08109029508629187.
   Google Scholar
• People over profits: Make COVID-19 medicines and vaccines free and fair for all. Oxfam International. 2020. [cited 2023 Aug 7]. Available from: https://www.oxfam.org/en/blogs/people-over-profits-make-covid-19-medicines-and-vaccines-free-and-fair-all.
   Google Scholar
• Safi M. Oxford/AstraZeneca Covid vaccine research ‘was 97% publicly funded’. The Guardian. 2021. [cited 2023 Dec 9]. Available from: https://www.theguardian.com/science/2021/apr/15/oxfordastrazeneca-covid-vaccine-research-was-97-publicly-funded. (accessed Dec 9, 2023).
   Google Scholar
• Lalani HS, Nagar S, Sarpatwari A, et al. US public investment in development of mRNA covid-19 vaccines: retrospective cohort study. BMJ. 2023;380:e073747. doi:10.1136/bmj-2022-073747.
   PubMedGoogle Scholar
• Lack of a real IP waiver on COVID-19 tools is a disappointing failure for people. | MSF. Médecins Sans Frontières (MSF) International. 2022. [cited 2023 Aug 15]. Available from: https://www.msf.org/lack-real-ip-waiver-covid-19-tools-disappointing-failure-people.
   Google Scholar
• World has entered stage of ‘vaccine apartheid’ - WHO head. Reuters. 2021. [cited 2023 Aug 7]. Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/world-has-entered-stage-vaccine-apartheid-who-head-2021-05-17/.
   Google Scholar
• The Politics of Vaccination: A Global History. Manchester University Press, 2017. [cited 2023 Aug 15]. Available from: https://www.jstor.org/stable/j.ctt1wn0s1m.
   Google Scholar
• Rai AK, Eisenberg RS. Bayh-Dole reform and the progress of biomedicine: allowing universities to patent the results of government-sponsored research sometimes works against the public interest. Am Sci. 2003;91(1):52–59. doi:10.1511/2003.11.52.
   Web of Science ®Google Scholar
• Swaminathan S, Pécoul B, Abdullah H, et al. Reboot biomedical R&D in the global public interest. Nature. 2022;602(7896):207–210. doi:10.1038/d41586-022-00324-y.
   PubMed Web of Science ®Google Scholar
• Galkina Cleary E, Jackson MJ, Zhou EW, et al. Comparison of research spending on new drug approvals by the national institutes of health vs the pharmaceutical industry, 2010-2019. JAMA Health Forum. 2023;4(4):e230511. doi:10.1001/jamahealthforum.2023.0511.
   PubMedGoogle Scholar
• Schuhmacher A, Hinder M, Boger N, et al. The significance of blockbusters in the pharmaceutical industry. Nat Rev Drug Discov. 2022;22(3):177–178. doi:10.1038/d41573-022-00213-z.
   Web of Science ®Google Scholar
• Dolgin E. Big pharma moves from ‘blockbusters’ to ‘niche busters. Nat Med. 2010;16(8):837–837. doi:10.1038/nm0810-837a.
   Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. New drugs at FDA: CDER’s new molecular entities and new therapeutic biological products. FDA. 2023. [cited 2023 Aug 7]. Available from: https://www.fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products.
   Google Scholar
• Beasley D. U.S. new drug price exceeds $200,000 median in 2022. Reuters. 2023. [cited 2023 Aug 7]. Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/us-new-drug-price-exceeds-200000-median-2022-2023-01-05/.
   Google Scholar
• Wouters OJ, Berenbrok LA, He M, et al. Association of research and development investments with treatment costs for new drugs approved from 2009 to 2018. JAMA Netw Open. 2022;5(9):e2218623. doi:10.1001/jamanetworkopen.2022.18623.
   PubMed Web of Science ®Google Scholar
• Torreele E. Global health should not be determined by pharma investors and shareholders. STAT. 2022. [cited 2023 Aug 15]. Available from: https://www.statnews.com/2022/05/03/pharma-investors-shareholders-should-not-determine-global-health/.
   Google Scholar
• World Health Organization. Resolution WHA72.8: Improving the transparency of markets for medicines, vaccines, and other health products. 2019. [cited 2023 Aug 15]. Available from: https://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_R8-en.pdf.
   Google Scholar
• Barrenho E, Lopert R. Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets. Paris: OECD; 2022. [cited 2023 Aug 15]. Available from: doi:10.1787/c9250e17-en.
   Google Scholar
• Ross JS, Gross CP, Krumholz HM. Promoting transparency in pharmaceutical industry–sponsored research. Am J Public Health. 2012;102(1):72–80. doi:10.2105/AJPH.2011.300187.
   PubMed Web of Science ®Google Scholar
• EU unable to cap COVID-19 vaccine prices in secret deals. Investigate Europe. 2021. [cited 2023 Dec 9]. Available from: https://www.investigate-europe.eu/posts/eu-negotiators-covid-19-vaccine-price-moderna-pfizer.
   Google Scholar
• Leo L, Satija B, Satija B. US FDA approves two gene therapies for sickle cell disease. Reuters. 2023. [cited 2023 Dec 10]. Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/us-approves-two-gene-therapies-sickle-cell-disease-2023-12-08/.
   Google Scholar
• Wingrove P, Erman M. Drugmakers set strategy for legal fight against US pricing regulation. Reuters. 2023. [cited 2023 Aug 15]. Available from: https://www.reuters.com/legal/drugmakers-set-strategy-legal-fight-against-us-pricing-regulation-2023-05-09/.
   Google Scholar
• Corporate Observatory Europe. High Prices, Poor Access. 2019. [cited 2023 Dec 8]. Available from: https://corporateeurope.org/sites/default/files/2019-05/High%20Prices%2C%20Poor%20Access_Full%20report.pdf.
   Google Scholar
• Push for drug pricing transparency strikes a nerve with industry. SWI swissinfo.ch. 2019. [cited 2023 Aug 11]. Available from: https://www.swissinfo.ch/eng/business/world-health-assembly_push-for-drug-pricing-transparency-strikes-a-nerve-with-industry/44969974.
   Google Scholar
• OpenSecrets. Pharmaceuticals/health products lobbying profile. OpenSecrets. 2023. [cited 2023 Aug 17]. Available from: https://www.opensecrets.org/federal-lobbying/industries/summary?id=H04.
   Google Scholar
• Angelis A, Polyakov R, Wouters OJ, et al. High drug prices are not justified by industry’s spending on research and development. BMJ. 2023;380:e071710. doi:10.1136/bmj-2022-071710.
   PubMedGoogle Scholar
• Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002;324(7342):886–891. doi:10.1136/bmj.324.7342.886.
   PubMed Web of Science ®Google Scholar
• Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley lecture. JAMA Otolaryngol Head Neck Surg. 2014;140(12):1225–1236. doi:10.1001/jamaoto.2014.1570.
   PubMed Web of Science ®Google Scholar
• Pedrique B, Strub-Wourgaft N, Some C, et al. The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment. Lancet Glob Health. 2013;1(6):e371-379–e379. doi:10.1016/S2214-109X(13)70078-0.
   Web of Science ®Google Scholar
• Plackett B. Why big pharma has abandoned antibiotics. Nature. 2020;586(7830):S50–S52. doi:10.1038/d41586-020-02884-3.
   Web of Science ®Google Scholar
• Selviaridis K, Dube N. Antibiotics shortages: what’s causing them and how countries can minimise the impact. The Conversation. 2022. [cited 2023 Aug 7]. Available from: http://theconversation.com/antibiotics-shortages-whats-causing-them-and-how-countries-can-minimise-the-impact-196540.
   Google Scholar
• Torreele E, Boum Y, Adjaho I, et al. Breakthrough treatments for ebola virus disease, but no access-what went wrong, and how can we do better? Lancet Infect Dis. 2023;23(7):e253–e258.
   PubMed Web of Science ®Google Scholar
• Prescrire’s ratings of new drugs in 2021: a brief review. Prescrire International. 2022;31(236):100–102.
   Google Scholar
• Vokinger KN, Glaus CEG, Kesselheim AS, et al. Therapeutic value of first versus supplemental indications of drugs in US and Europe (2011–20): retrospective cohort study. Br Med J. 2023;382:e074166.
   PubMedGoogle Scholar
• Dickson S, Ballreich J. How much can pharma lose? A comparison of returns between pharmaceutical and other industries. West Health Policy Centre, 2019. cited 2023 Aug 7]. Available from: https://www.westhealth.org/press-release/new-analysis-finds-large-drug-makers-could-lose-1-trillion-in-sales-and-still-be-the-most-profitable-industry/.
   Google Scholar
• Ledley FD, McCoy SS, Vaughan G, et al. Profitability of large pharmaceutical companies compared with other large public companies. J Am Med Assoc. 2020;323(9):834–843. doi:10.1001/jama.2020.0442.
   Web of Science ®Google Scholar
• The WHO Council on the Economics of Health for All. Governing health innovation for the common good - Council Brief No. 1. 2023. [cited 2023 April 22]. Available from: https://www.who.int/publications/m/item/governing-health-innovation-for-the-common-good.
   Google Scholar
• Lazonick W, Tulum Ö. Sick with “Shareholder Value”: US Pharma’s Financialized Business Model During the Pandemic. Institute for New Economic Thinking, 2022. [cited 2023 Dec 8]. Available from: https://www.ineteconomics.org/uploads/papers/LazonickTulum-Pharma.pdf.
   Google Scholar
• Investors bite the big pharma hands that feed them. Evaluate.com. 2022; cited 2023 Aug 7]. Available from: https://www.evaluate.com/vantage/articles/insights/other-data/investors-bite-big-pharma-hands-feed-them.
   Google Scholar
• Torreele E, McNab C, Adeyi O, et al. It is time for ambitious, transformational change to the epidemic countermeasures ecosystem. Lancet. 2023;401(10381):978–982. doi:10.1016/S0140-6736(23)00526-3.
   PubMed Web of Science ®Google Scholar
• Torreele E, Kazatchkine M, Mazzucato M. Preparing for the next pandemic requires public health focused industrial policy - BMJ. 2022. [cited 2023 Dec 24]. Available from: https://blogs.bmj.com/bmj/2021/04/01/preparing-for-the-next-pandemic-requires-public-health-focused-industrial-policy/.
   Google Scholar
• Torreele E, Wolfe D, Kazatchkine M, et al. From private incentives to public health need: rethinking research and development for pandemic preparedness. Lancet Glob Health. 2023;11(10):e1658–1666–e1666. doi:10.1016/S2214-109X(23)00328-5.
   Web of Science ®Google Scholar
• House Democrats probe finds drugmakers drove U.S. price hikes. POLITICO. 2021. [cited 2023 Aug 11]. Available from: https://www.politico.com/news/2021/12/10/house-democrats-drugmakers-price-hikes-524079.
   Google Scholar
• HJI and Multi Stakeholder Group. Analysis finds South Africa was bullied into Covid-19 vaccine contracts. Daily Maverick. 2023. [cited 2023 Sept 11]. Available from: https://www.dailymaverick.co.za/article/2023-09-11-analysis-finds-sa-was-bullied-into-one-sided-imperial-and-immoral-covid-19-vaccine-contracts/.
   Google Scholar
• Apuzzo M, Gebrekidan S. Governments sign secret vaccine deals. Here’s what they hide. The New York Times. 2021. [cited 2023 Aug 11]. Available from: https://www.nytimes.com/2021/01/28/world/europe/vaccine-secret-contracts-prices.html.
   Google Scholar
• Mazzucato M. The value of everything. Making and taking in the global economy. Allen Lane. New York: PublicAffairs; 2018,384. ISBN 978-161039675-2
   Google Scholar
• Universal Declaration of Human Rights. United Nations. [cited 2023 Dec 11]. Available from: https://www.un.org/en/about-us/universal-declaration-of-human-rights.
   Google Scholar